Ascendis Pharma is committed to developing a proprietary pipeline of unique products that address unmet patient needs in rare endocrine diseases. Our ongoing clinical programs for TransCon hGH, TransCon PTH, and TransCon CNP are a reflection of that commitment.
|A global phase 2 clinical trial designed to evaluate the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism. The trial will also evaluate a titration regimen for the complete withdrawal of standard of care (i.e., active vitamin D and calcium supplements).
|A natural history study designed to gain insight into the experience of children with achondroplasia. ACHieve will study height velocity, body proportionality, and comorbidities over time of children with achondroplasia up to 8 years old. No study medication will be administered.